Fibromyalgia Treatment Market to Surpass US$ 4,079.0 Mn by 2030 - Coherent Market Insights

Global Fibromyalgia Treatment Market, by Drug Class (Antidepressants (Milnacipran (Savella and Other Generics), Duloxetine (Cymbalta and Other Generics), and Others), Antiepileptics (Pregabalin (Lyrica and Other Generics), and Others), Muscle Relaxants, Analgesics, and Others (Including Pipeline Drugs)), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 3,142.4 Million in 2022 and is expected to exhibit a CAGR of 3.3% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.

Increased research and development for fibromyalgia treatment is expected to drive the market over the forecast period. For instance, in April 2022, the investigators Massachusetts General Hospital were doing this research study to explore whether the bacillus Calmette-Guérin (BCG) vaccine can be an effective treatment for fibromyalgia. The researchers believe that the BCG vaccine can benefit people with fibromyalgia by increasing immune signaling molecules, called cytokines. The study is in phase 2 Clinical Trial: Multi-dosing the BCG Vaccine for Fibromyalgia and was initiated in January 2022. The primary completion of study is estimated to be at January 2023.

Global Fibromyalgia Treatment Market– Impact of Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors, including the private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry, mainly due to strict lockdown in several regions. Private healthcare is one such sector that has been impacted significantly by the COVID-19 pandemic.

However, the COVID-19 pandemic had a positive impact on the global fibromyalgia treatment market, owing to its possible association with the COVID-19 infection. For instance, in September 2021, according to the data generally, fibromyalgia (FM) increases during stressful situations and after traumatic exposure. Fibromyalgia, as a chronic syndrome of unknown cause with widespread body pain, fatigue, sleep disorder, cognitive impairment and anxiety. Many studies have shown a relationship between pain levels and anxiety levels in patients with fibromyalgia. Covid-19 started from Wuhan, China in December 2019 and spread worldwide. The rapid spread of this unexpected pandemic all over the world brought with it many conditions such as anxiety and stress disorders. It has been reported by experts that individuals with a predisposition to conditions such as anxiety and stress disorder in premorbidity require special attention. To evaluate the psychological effects of the Covid-19 pandemic, the Covid-19 anxiety scale was developed from Lee et al. and the Covid-19 fear scale was developed from Ahoursou et al. The investigators planned to analyze the effect on Covid-19 fear and anxiety level on fibromyalgia patients' daily life with revised Fibromyalgia Impact questionnaire, sleep quality with Pittsburgh Sleep Quality Index, and anxiety-depression level with The Hospital Anxiety and Depression scale. This study was planned as a cross-sectional case control study.

Global Fibromyalgia Treatment Market: Key Developments

In May 2022, the Wearable TENS Device received the U.S. Food and Drug Administration De Novo authorization for use as an aid in reducing the symptoms of fibromyalgia in adults with high pain sensitivity. Quell (Wearable TENS Device) is a transcutaneous electrical nerve stimulator (TENS) that is worn on the upper calf. The device delivers electrical stimulation to the user through a disposable electrode. The primary endpoint of the study was patients’ global impression of change (PGIC), measured on a 7 point scale depicting a patient’s rating of overall improvement.

Browse 32 Market Data Tables and 35 Figures spread through 176 Pages and in-depth TOC on “Global Fibromyalgia Treatment Market”-  Forecast to 2030, Global Fibromyalgia Treatment Market, by Drug Class (Antidepressants (Milnacipran (Savella and Other Generics), Duloxetine (Cymbalta and Other Generics), and Others), Antiepileptics (Pregabalin (Lyrica and Other Generics), and Others), Muscle Relaxants, Analgesics, and Others (Including Pipeline Drugs)), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/fibromyalgia-treatment-market-1691

Moreover, major players in the market are actively engaged in launch of fibromyalgia treatment to establish or retain market position. For instance, in December 2019, Eli Lilly and Company, Pharmaceutical Company, announced the launch of TRIUMPH, a long-term, real-world evidence study of Emgality (galcanezumab-gnlm). The galcanezumab-gnlm is studied preventive treatments for migraine. The Emgality (galcanezumab-gnlm) is administrated by the Fibromyalgia patients to treat the serve headache and as antidepressant.

Key Takeaways of the Global Fibromyalgia Treatment Market:

• The global fibromyalgia treatment market is expected to exhibit a CAGR of 3.3% during the forecast period due to the increasing research and development activities by the key players in the market. For instance, in April 2022, Tonix Pharmaceuticals, Inc., a biotech company is carrying out phase 3 study on Drug: TNX-102 SL. This is a Phase 3, randomized, parallel-group, double-blind, placebo-controlled, 14-week study designed to evaluate the efficacy and safety of TNX-102 SL 5.6 mg (2 x 2.8 mg tablets) taken daily at bedtime for the treatment of fibromyalgia. The phase 3 study started at April 6, 2022 and estimated primary completion date at June 2023.
• Manufacturers intend to take advantage of countries with large population such as India and China, wherein healthcare infrastructure is steadily getting better (especially in India). Generic manufacturers such as Mylan N.V. and Teva Pharmaceutical Industries Ltd offer their generic versions of fibromyalgia treatment medications.
• Among regions, North America is estimated to account for the largest market share in the global fibromyalgia treatment market over the forecast period, owing to the increasing prevalence of the fibromyalgia. For instance, in May 2022, according to data published by the National Center for Biotechnological Information, fibromyalgia affects about 4 million U.S. adults in 2021, about 2% of the adult population. Fibromyalgia is more common in women compared to men, with the prevalence of fibromyalgia in the U.S. at 6.4% (7.7% in women and 4.9% in men).
• Major players operating in the global fibromyalgia treatment market include Eli Lilly and Company, Pfizer, Inc., Novartis AG, Allergan plc., Sun Pharmaceutical Industries Ltd., Aptinyx, Inc., Prismic Pharmaceuticals, Inc., Innovative Med Concepts, Inc., Intec Pharma Ltd., and Astellas Pharma Inc.